特朗普，突然出手！杀伤力有多大？

Core Viewpoint - The article discusses President Trump's announcement of a new drug pricing policy aimed at reducing prescription drug prices in the U.S. by 30% to 80%, which has led to a decline in pharmaceutical stocks in both U.S. and A-share markets [1][3][6]. Group 1: Policy Announcement - Trump plans to sign an executive order to lower prescription drug costs "almost immediately" by 30% to 80% [3]. - The announcement raises questions about why U.S. drug prices are significantly higher than those in other countries, sometimes 5 to 10 times more for the same drug [3]. - The policy may primarily affect drugs covered by Medicare and Medicaid, which together account for about 40% of the U.S. drug payment market [6][8]. Group 2: Market Reaction - Following the announcement, U.S. pharmaceutical stocks fell sharply, with notable declines in companies like Novo Nordisk (down 5.25%) and AbbVie (down 4.12%) [1]. - The A-share pharmaceutical sector also showed weakness, particularly in innovative drug stocks [1][6]. Group 3: Implications for Drug Pricing - The proposed policy links U.S. drug prices to those paid by other developed countries, which may face strong opposition from the pharmaceutical industry [4]. - The actual impact of the price reductions may be limited, as the negotiation power of the federal government over drug prices was previously restricted [6][7]. - The article highlights the significant difference between the list price (WAC) and the net price that consumers actually pay, indicating that a reduction in list prices may not substantially affect overall drug costs [7][8].